The Seventh Circuit Court of Appeals has upheld the convictions of Rishi Shah and Shradha Agarwal, who were found guilty of orchestrating a multi-million-dollar fraud scheme through their healthcare technology company, Outcome Health. The court's decision, made on August 6, 2026, comes after a lengthy legal battle that included an 11-week trial and multiple appeals. This ruling is significant as it reinforces the government's ability to prosecute corporate fraud and maintain asset restraint during legal proceedings.
Shah and Agarwal, both prominent figures in the healthcare technology sector, were indicted in 2019 for their roles in a scheme that defrauded clients and investors by inflating performance metrics and overstating the availability of advertising space on Outcome's platforms. Their convictions included multiple counts of mail, wire, and bank fraud, as well as money laundering charges against Shah. The case has drawn attention not only for the scale of the fraud but also for the legal arguments surrounding the defendants' rights to counsel during the trial.
The background of this case dates back to 2006 when Rishi Shah founded Outcome Health, which provided advertising solutions in healthcare settings. Shradha Agarwal joined the company shortly after and eventually became its President. The company grew rapidly, but in 2017, allegations surfaced that it had been deceiving clients by overselling advertising space and misrepresenting performance data. Following a Wall Street Journal report, federal charges were filed against Shah and Agarwal, leading to their indictment in November 2019.
During the trial, the prosecution presented evidence showing that the defendants had knowingly inflated advertising metrics and misled clients about the availability of advertising space. The jury found Shah guilty on multiple counts, sentencing him to 90 months in prison, while Agarwal received a lesser sentence of one day in prison. Both were also ordered to forfeit millions of dollars linked to their fraudulent activities.
Shah and Agarwal appealed their convictions primarily on the grounds that a pretrial protective order had improperly frozen their assets, which they argued violated their Sixth Amendment right to counsel. They claimed that the asset freeze limited their ability to pay for their preferred legal representation, thereby impacting their defense. The court ruled that while the asset freeze was expansive, it did not violate their rights, as they had sufficient information to challenge the restraint before the trial began.
In its opinion, the court stated, "We see no error in the district court’s finding that Shah and Agarwal received sufficient information during discovery to identify and challenge the over-restraint well before trial." This ruling highlights the court's view that the defendants had adequate opportunity to address their concerns regarding asset restraint prior to the trial.
The impact of this ruling extends beyond Shah and Agarwal. It reinforces the government's ability to impose asset freezes in cases of alleged fraud, ensuring that funds potentially linked to criminal activity can be preserved for restitution or forfeiture. This decision may also serve as a precedent for future cases involving asset restraint and defendants' rights, clarifying the balance between protecting defendants' rights and the government's interest in prosecuting fraud.
Looking ahead, it remains to be seen whether Shah and Agarwal will pursue further legal avenues, including a possible appeal to the Supreme Court. However, the Seventh Circuit's ruling appears to solidify their convictions and the legal framework surrounding asset restraint in fraud cases. The case underscores the importance of transparency and accountability in corporate practices, particularly in the healthcare sector, where trust is paramount.